Numerous cancer drug discovery projects have focused on the design of Hsp90 inhibitors, mainly targeting the N‐terminal domain, inspired by the benzoquinone‐containing natural product geldanamycin and synthetic derivatives (Kitson et al. 2024). Here, HSP90AA1 is linked to cancer.